Meloxicam: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Meloxicam. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| No. of patients | 157% |
| Gastrointestinal | 28.1% |
| Gastrointestinal disorders | 18.9% |
| Headache | 10.2% |
| Diarrhea | 9.2% |
| Nausea | 7.2% |
| Urinary tract infection | 6.9% |
| Dyspepsia | 6.5% |
| Headaches nos * | 6.4% |
| Influenza-like symptoms | 5.8% |
| Dyspeptic signs and symptoms† | 5.8% |
| Arthralgia | 5.3% |
| Pain | 5.2% |
| Flatulence | 4.5% |
| Accident household | 4.5% |
| Edema | 4.5% |
| Anemia | 4.1% |
| Dizziness | 3.8% |
| Nausea * | 3.8% |
| Insomnia | 3.6% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
1 INDICATIONS AND USAGE 1.1 Osteoarthritis (OA) Meloxicam tablets are indicated for relief of the signs and symptoms of osteoarthritis [see Clinical Studies (14.1)]. 1.2 Rheumatoid Arthritis (RA) Meloxicam tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis [see Clinical Studies (14.1)]. 1.3 Juvenile Rheumatoid Arthritis (JRA) Pauciarticular and Polyarticular Course Meloxicam tablets are indicated for relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients who weigh ≥60 kg [see Dosage and Administration (2.4) and Clinical Studies (14.2)].
Medical disclaimer: Always consult a qualified healthcare professional about any medication.